Given the obvious quality of life concerns with medical and surgical lowering of intraocular pressure (IOP), lasers have received considerable attention as a therapeutic modality for glaucoma.
INTRODUcTION
Glaucoma is a progressive optic neuropathy and may lead to irreversible blindness. It is one of the leading causes of blindness, worldwide. 1 The only known modifiable risk factor for disease onset and progression is intraocular pressure (IOP), the reduction of which may slow down progression in glaucoma.
Given the obvious quality of life concerns with medical and surgical lowering of IOP, lasers have received considerable attention as a therapeutic modality for glaucoma.
Laser application to the trabecular meshwork (TM) or laser trabeculoplasty (LTP) has been used since the early 1970s. It was first described in 1973 by Worthen and Wickham, 2 using an argon laser to perform trabeculoplasty, and by Krasnov 3 using a Q-switched ruby laser to perform goniopuncture or laser puncture. It was not until 1979 that Wise and Witter 4 described a modified technique to perform argon laser trabeculoplasty (ALT), which subsequently gained acceptance as a therapeutic option of open-angle glaucoma (OAG). Since then, it has been seen that trabeculoplasty can also be performed with Krypton lasers, 5 continuous wave neodymium lasers 6 and diode lasers 7 with results similar to those seen with ALT.
In the glaucoma laser trial follow-up study, after 7 years of follow-up, patients with ALT had lower IOP than patients on medical treatment (the glaucoma laser trial research group 1990, 1995). 8 ,9 LTP appears to be less costly than current medical treatment. 10 LTP can lower IOP without relying on patient compliance with medications, which has been repeatedly shown to be a common problem. [11] [12] [13] [14] By replacing or decreasing the need for topical medications, LTP can reduce systemic side effects, such as cardiorespiratory depression 15 and local side effects, such as allergy, 16 chronic inflammation 17, 18 which may decrease the success rate of future filtration surgery 19 and cosmetic changes. 20 Selective laser trabeculoplasty (SLT) was listed by the FDA in 2002 as a procedure separate from ALT. SLT is the delivery of laser energy to TM using parameters such that the result is the selective absorption of energy by pigmented cells, sparing adjacent cells and tissues from thermal damage. Although the mechanism of its action is even less well understood than that of ALT, it provides IOP reduction that is similar in magnitude and duration to that obtained with ALT, is associated with very few complications and offers several other potential advantages over ALT.
This review attempts a broad overview of the current knowledge of its mechanism, efficacy, indications and limitations point out the knowledge lacunae that still exist with respect to this highly promising technology which has captured the attention of glaucoma surgeons all over the world.
MEcHANISM OF AcTION OF SLT
This procedure is called SLT because there is a selective effect on melanotic elements associated with the meshwork. SLT is possible because pigmented TM cells exhibit greater optical absorbance of the applied laser energy than the cells that surround them. 21 Histologic studies have shown that there is less coagulative damage after SLT and less structural change of the meshwork. 22 A short burst of laser energy heats and thermally damages pigmented TM cells before neighboring cells have a chance to absorb enough laser energy to incur any thermal damage. 23 Latina and Park have demonstrated selective killing of the cultured, pigmented TM cells over nonpigmented TM cells using the principles of selective photothermolysis (SP). [23] [24] [25] [26] The pigmented TM endothelial cells have melanin as the intracellular pigment and, thus, it is possible to confine the damage to these cells using the principles of SP. This approach relies on selective targeting of the pigmented TM cells using single laser pulses of short pulse duration and low fluencies (energy/area), to generate and confine heat to the pigmented cells. 23 One important characteristic of the principle of SP is that multiple targeting of only the pigmented TM cells can be affected simultaneously without using focusing to achieve specificity. Using a short laser pulse confines the thermal damage to the cell containing the pigment target, if the duration of the laser pulse is equal to or less than the thermal relaxation time of the intracellular pigment. 23, 27 The thermal relaxation time of melanin is approximately 1 millisecond and the pulse duration of SLT laser is 3 nanosecond, and this essentially prevents thermal dissipation to surrounding tissues. 27 The large spot size in SLT (400 mm) versus the small spot size in ALT (50 mm) also ensures that low fluences can be maintained, which is necessary to prevent collateral thermal damage to the surrounding tissues. 23 Although melanin has a broad absorption spectrum, it has been shown that for the destruction of melanin-containing cells, a wavelength of about 504 nm seems optimal. 23, 28 The mechanism of action of SLT has been explained by biological theory which suggests that trabecular photoco agu lation stimulates some biologic response that could contribute to eventual reduction in the IOP. 29 Although ALT destroys both the pigmented and the nonpigmented TM endothelial cells at the burn site, it has been shown in studies using human TM maintained in organ culture model that, after ALT, the trabecular cells in the region near the Schwalbe line are stimulated to divide.
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This cell division seemed to occur not only in the half treated with laser photocoagulation but also in the opposite 180° nonlasered TM segments. No stimulation of the corneal endothelial cells or trabecular overgrowth by these cells was noted in these studies. It has been suggested that perhaps these cells in the anterior nonfiltering portion of the TM are multipotent cells, and that injury to the trabeculum from laser trabeculoplasty stimulates them to divide, to migrate and repopulate the TM beams at the burn sites, to fabricate a new extracellular matrix or phagocytize. 32 Although the precise barriers to aqueous humor outflow are not understood, it has been suggested that the proteoglycan components of the extracellular matrix are significant contributors. 33, 34 It has been shown that argon laser photocoagulation of the TM causes alteration in the turnover or synthesis of trabecular extracellular matrix and this might result in an improvement in the aqueous outflow. 35 The stimulation of the trabecular cells with an increase in their phagocytic activity, after the ALT, might also help in cleaning the TM of any 'clogging' debris.
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Predictive Factors of SLT Success
The predictors of success following SLT have been studied in various population, and the results obtained have been found to be similar, though not identical. This may be attributed to the fact that the population studied varied in terms of race, age, severity of glaucoma and also SLT treatment protocols (Table 1) . Gracner et al 37 reported a negative correlation between successful SLT and the grade of TM pigmentation and Table 3 .
SLT comparison to ALT
Damji et al
53 prospectively performed 180° of SLT or ALT in a randomized fashion in 36 eyes of 34 patients with various forms of OAG. Some eyes had been previously treated with ALT. Average IOP and change in IOP did not differ statistically significantly between the two groups during 6 months of follow-up. At 6 months, IOP was reduced by 4.8 to 3.4 mm Hg in the SLT group and 4.7 to 3.3 mm Hg in the ALT group. Anterior chamber reaction was quantitated only 1 hour after the laser treatment, when there were, on average, statistically significantly more cells in eyes that had SLT and a similar amount of flare in both groups. These investigators subsequently extended their study to 176 eyes of 152 followed for 12 months. There was no statistically significant difference between IOP in the two groups at any time point from baseline to 12 months. At 12 months, IOP was reduced by a mean -5.86 to 6.1 mm Hg in the SLT group and -6.0 to 4.8 mm Hg in the ALT group. Importantly, it should be realized that the results of this study reflect a 'real-life' scenario more than a controlled study, because medication change, additional laser treatment and surgery were allowed during the study period and are partly responsible for the resulting IOP, in addition to the initial laser. Juzych et al 54 conducted a retrospective analysis to compare the longer-term outcomes of SLT with ALT. They reviewed the charts of all patients with uncontrolled chronic OAG who were treated with laser trabeculoplasty over a 6-month period by the same surgeon. Of these patients, 154 were treated with ALT and 41 with SLT patients. Preoperatively, patients in both groups had a similar IOP (23.9-2.6 in SLT group, 24.3-4.1 in ALT group) been using a similar average number of glaucoma medications (2.5-1.3 in SLT group, 2.5-1.2 in ALT group). Follow-up ranged from 3 to 60 months (mean, 32.5-15.9 months). 
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The results of the main comparative studies are summarized in Table 4 .
HOW MUcH ANGLE IS TO BE TREATED?
The principle of therapy by any modality is to apply the minimum amount of treatment necessary to achieve the maximum desired therapeutic with minimum adverse effects. As proved by many studies, SLT has a dose response effect.
In the study by Nagar et al, 50 90° SLT treatment produced lower success rates than either 180 or 360° SLT; the higher success rates with 360° SLT compared with 180° SLT did not reach the level of statistical significance ocular pain but not anterior chamber inflammation or the rate of IOP spikes was increased in eyes receiving 360 vs 90° SLT. hypertension and primary open angle glaucoma who received SLT as primary therapy without any subsequent medical or surgical intervention followed up for a period of 2 years. Forty-one eyes were treated by SLT, 19 eyes in the 180° group and 22 eyes in the 360° group. The mean reduction in IOP at 2 years was 28% in 180° group and 35% in 360° SLT group. After the SLT, the 360° SLT group had a lower IOP fluctuation compared with the 180° SLT group over the follow-up period of months 6 to 24 months. This study suggests that 360° SLT is more efficacious in achieving smaller IOP fluctuations than treatment with 180° SLT.
Ayala et al 61 conducted a retrospective chart review of eyes that underwent SLT. The primary outcome measure was time to failure after SLT treatment, 120 eyes of 120 patients were identified. The average time to failure after SLT was 18 months. The success rate after 12 months was 62%, after 24 months 34%, after 36 months 28% and after 48 months 24%. The long-term effects of SLT, when eyes were treated over 90°, seem to be low. They recommend treating patients over 180°. The results of the main clinical evaluations are summarized in Table 5 .
SLT IN DIFFERENT SUBTYPES OF GLAUcOMA
SLT is commonly used to treat patients with open angle glaucoma, (i.e. primary open-angle glaucoma, pigmentary glaucoma, exfoliative glaucoma). However, recent studies have examined the efficacy and safety of SLT to lower IOP in other glaucoma subtypes as well. Although limited by small sample sizes and lack of control groups, these studies suggest an expanding clinical role for LTP.
SLT in PAcG
SLT seems to be a safe and effective method of reducing IOP in many eyes with primary angle closure and a patent iridotomy in which there is a sufficient extent of visible TM. Ho et al 62 conducted a multicentric, prospective, noncontrolled clinical trial to determine, whether SLT can lower intraocular pressure in eyes with chronic primary angle closure, elevated IOP, and a patent iridotomy. Sixty eyes of 60 patients with chronic angle closure who had undergone iridotomy, had an IOP greater than 21 mm Hg and a gonioscopically visible pigmented TM for at least 90° were enrolled. SLT was applied to open angle segments. Patients were followed-up for 6 months. The mean baseline IOP was 24.6 ± 2.5 mm Hg. At 6 months, IOP reduction of Retrospective chart 120 eyes 18 months They recommend treating review patients over 180° TM 3 or 4 mm Hg was measured in 82 and 72% of eyes respectively, and IOP reduction of 20 or 30% was measured in 54 and 24% of eyes respectively .There were no significant complications attributable to SLT.
SLT in Steroid-induced Glaucoma
Steroid-induced glaucoma has become common with the rise in usage of intravitreal steroids to treat a variety of posterior segment disorders. There have been very few studies to assess the efficacy of SLT in steroid-induced glaucoma.
SLT is a temporizing procedure to consider in patients with steroid induced elevated IOP. interventional case series to evaluate the prophylactic efficacy of SLT for preventing an increase in IOP after IVTA injection, they studied 31 eyes with a baseline IOP of 21 mm Hg or more of 31 patients for which IVTA injection was planned for diabetic macular edema. The patients were divided into two groups. 43 found that after 1 and 4 months, the presence of XFG had no effect on post-SLT IOP reduction, but was significantly more prevalent in eyes that did not have retreatment, suggesting an association with increased success rate after SLT. One subgroup analysis showed that 1 year after SLT, XFG glaucoma was not associated with a different outcome compared with OAG. These preliminary findings suggest that SLT is effective in eyes with XFG, with similar efficacy to eyes with OAG and similar efficacy to that of ALT.
SLT in Normal Tension Glaucoma (NTG)
El Mallah et al 68 
SLT in Heavily Pigmented TM
There is some evidence showing a correlation between the degree of angle pigmentation and the effectiveness of SLT. The study by Van rate of anterior chamber inflammation in eyes receiving 360° SLT vs 0% in latanoprost-treated eyes. A single case report of hyphema after SLT has also been reported.
Ocular Discomfort
Latina et al 48 reported that 15% of eyes receiving SLT reported discomfort after the procedure. Martinez-de-la-Casa et al 55 evaluated postoperative pain using a 10-point scale and found significantly lower pain scores after SLT compared with ALT during and immediately after treatment; these differences were gone by 24 hours posttreatment. Nagar et al 50 reported a 39% rate of discomfort in eyes undergoing 360° SLT and a 0% rate in eyes receiving latanoprost.
Repeat Selective Laser Trabeculoplasty
SLT is becoming an increasingly popular alternative to ALT in the treatment of open-angle forms of glaucoma, primarily owing to the lack of collateral thermal damage and TM scarring with SLT as compared with ALT. Since SLT delivers only one tenth of the energy compare with ALT and it causes minimal thermal damage to TM it has a greater potential of repeatability. Since its approval, there have been very few studies to study the efficacy of repeatability of SLT despite of strong theoretical proof for it. Bryan Kun Hong et al 71 conducted a retrospective chart review of forty-four eyes of 35 patients, underwent an initial 360° SLT (SLT1), which was successful for 6 months, but eventually lost efficacy and was followed by a repeat 360° SLT (SLT2). Using a definition of 'success' as >20% peak IOP reduction, success rates for SLT1 and SLT2 were not significantly different. They concluded that repeat 360° SLT may be safe and effective after an initially successful 360° SLT has failed.
comparative Analysis of cost of Medical Management with SLT
There has been many studies to prove that the common cause of failure of medical management in glaucoma is lack of compliance. Nordstorm et al 72 did a retrospective cohort study using health insurance claims data of newly treated individuals with diagnosed glaucoma (n = 3623) and suspect glaucoma (n = 1677), and concluded that many patients fail to use topical medications as prescribed. Nearly one half of the individuals who had filled a glaucoma prescription discontinued all topical ocular hypotensive therapy within 6 months, and just 37% of these individuals recently had refilled their initial medication at 3 years after the first dispensing .The other cause of failure of reported is cost of glaucoma medication. 
cONcLUSION
SLT is increasingly being used in clinical practice as both, the primary procedure and as an adjunct to medical and surgical therapy. Preliminary published evidence suggests that SLT is a effective, compliance-free, repeatable and safe therapeutic modality having only minor, transient, selflimiting or easily controlled side effects with no sequelae. Also, the use of SLT has a better quality of life impact than medication or surgery. Its use has been found to be costsaving, thereby reducing the economic burden of the disease. However, the response rates within the first postoperative year have varied from 59 to 96%, according to different definitions. The reported average reduction in IOP from pretreatment IOP ranges from 18 to 40%, over a follow-up period of 6 to 12 months, with some authors reporting results for the whole cohort and others only for responders. Therefore, it must be emphasized that SLT is not a cure, and all patients must remain under regular follow-up.
